Emerging molecular therapies of advanced thyroid cancer

Catalano, Maria Graziella; Poli, Roberta; Pugliese, Mariateresa; Fortunati, Nicoletta; Boccuzzi, Giuseppe

doi:10.1016/j.mam.2010.02.006

Cited by 38 publications

(33 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to the therapy of thyroid cancer, besides radiation, new molecular therapies are emerging which employ kinase inhibitors, proteasome inhibitors, and epigenetic modulators (Catalano et al 2010), and some of these drugs have been shown to also affect the autophagy process. For instance, sorafenib and sunitinib, two small molecules that inhibit the activity of RET kinase and that are commonly used for the treatment of MTCs, were shown to induce autophagosome accumulation in MTC cultured cells (Lin et al 2012a,b).…”

Section: Ras-raf-erk and The Class I Pi3k-akt-mtor Pathwaysmentioning

confidence: 99%

Autophagy and thyroid carcinogenesis: genetic and epigenetic links

Morani¹,

Titone²,

Pagano³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

Thyroid cancer is the most common cancer of the endocrine system and is responsible for the majority of deaths from endocrine malignancies. Although a large proportion of thyroid cancers belong to well differentiated histologic subtypes, which in general show a good prognosis after surgery and radioiodine ablation, the treatment of radio-resistant papillarytype, of undifferentiated anaplastic, and of medullary-type thyroid cancers remains unsatisfactory. Autophagy is a vesicular process for the lysosomal degradation of protein aggregates and of damaged or redundant organelles. Autophagy plays an important role in cell homeostasis, and there is evidence that this process is dysregulated in cancer cells. Recent in vitro preclinical studies have indicated that autophagy is involved in the cytotoxic response to chemotherapeutics in thyroid cancer cells. Indeed, several oncogenes and oncosuppressor genes implicated in thyroid carcinogenesis also play a role in the regulation of autophagy. In addition, some epigenetic modulators involved in thyroid carcinogenesis also influence autophagy. In this review, we highlight the genetic and epigenetic factors that mechanistically link thyroid carcinogenesis and autophagy, thus substantiating the rationale for an autophagy-targeted therapy of aggressive and radio-chemo-resistant thyroid cancers.

show abstract

Section: Ras-raf-erk and The Class I Pi3k-akt-mtor Pathwaysmentioning

confidence: 99%

Autophagy and thyroid carcinogenesis: genetic and epigenetic links

Morani¹,

Titone²,

Pagano³

et al. 2013

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…New targeted therapies are thus regarded with increasing interest by both endocrinologists and oncologists [29,31]. After the publication of the DECISION trial, sorafenib -the first drug approved for this indication-represents the first-line systemic approach in this setting [26,27].…”

Section: Discussionmentioning

confidence: 99%

“…During tumour progression, cellular dedifferentiation occurs in up to 5% of cases, leading to poorly differentiated pathological features. These characteristics may include the loss of the ability to produce Tg [31].…”

Section: Discussionmentioning

confidence: 99%

Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center

et al. 2014

View full text Add to dashboard Cite

“…Thyroid cancer rate has been estimated to be around 1.5% at present. Among thyroid cancers, anaplastic thyroid cancer (ATC) is the most lethal with median survival time of 6 months following diagnosis (Catalano et al, 2010;Fassnacht et al, 2009). At the time of diagnosis, ATC is in the well advanced stage and reached to a size of around 8 cm.…”

Section: Introductionmentioning

confidence: 99%

Floroquinone induces apoptosis and inhibits carcinoma growth in mouse tumor xenograft model of anaplastic thyroid cancer

Zhao

Chen

Hao

et al. 2016

Bangladesh J Pharmacol

View full text Add to dashboard Cite

In the present study, effects of floroquinone on anaplastic thyroid cancer cell lines and mouse tumor xenografts were investigated. Increase in the concentration of floroquinone from 10 to 100 µM reduced the cell growth from 98 to 17% after 48 hours in HOTHC cells. Similarly, in FRO cells growth rate was found to be 96 and 21%, respectively at 10 and 100 µM concentra-tions of floroquinone. Western blot analysis showed a marked reduction in Bcl-2 expression and increased in Bax, caspase-3 and cleaved PARP expre-ssion in HOTHC cell lines on treatment with floroquinone. Floroquinone treatment of the HOTHC cells led to inhibition of the cobalt chloride-induced increase in the hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor expression. In HOTHC cells, floroquinone treatment inhibited the tube formation and migration potential significantly compared to control cells. Treatment of the mouse bearing HOTHC tumor xenograft with 50 and 100 mg/kg doses of floroquinone alternatively for one month reduced the tumor volume to 48 and 17%, respectively compared to the control. Thus, floroquinone effectively inhibits growth of thyroid cancer and can be used for its treatment.Video Clip:<a href="https://www.youtube.com/v/sub0JQlrffc">Migration assay</a>: 1 min 09 sec

show abstract

Emerging molecular therapies of advanced thyroid cancer

Cited by 38 publications

References 94 publications

Autophagy and thyroid carcinogenesis: genetic and epigenetic links

Autophagy and thyroid carcinogenesis: genetic and epigenetic links

Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center

Floroquinone induces apoptosis and inhibits carcinoma growth in mouse tumor xenograft model of anaplastic thyroid cancer

Contact Info

Product

Resources

About